C
CG Oncology
Focused on developing bladder cancer therapeutics
About CG Oncology
CG Oncology is a healthcare startup that specializes in oncolytic immunotherapy, a type of treatment that uses the body's immune system to fight cancer. The company's primary focus is on developing treatments that can save the bladder in patients suffering from bladder cancer. Their mission is to improve the quality of life for patients with urologic cancers, allowing them to live and work with dignity.
Read full description
Their leading product, cretostimogene grenadenorepvec, is an innovative immunotherapy treatment that is delivered directly into the bladder. This treatment has shown potential in treating Non-Muscle Invasive Bladder Cancer (NMIBC) that is unresponsive to Bacillus Calmette-Guérin (BCG), a common treatment for bladder cancer. The side effects of this treatment are in line with other similar therapies.
CG Oncology operates in the healthcare market, specifically in the field of oncology. Their business model revolves around the research, development, and commercialization of their immunotherapy treatments. They generate revenue through the sales of these treatments to healthcare providers and patients.
Recently, the company announced that they will be presenting interim Phase 3 data from their BOND-003 study at the upcoming 24th Annual Meeting of the Society of Urologic Oncology. They have also recently appointed new members to their executive team, including a new President and Chief Operating Officer, Chief Technical Officer, and Chief Medical Officer.
At a glance
- Founded
- 2010
- Headquarters
- Irvine, United States
- Listing
- IPO 2024
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Ally Bridge Group
WI Harper Group
Series B and later16 investors entered at this stage
Perseverance Capital Management- AFAsian Healthcare Fund
ORI Capital- KPKissei Pharmaceutical
Camford Capital
RA Capital Management
Longitude Capital
Decheng Capital- SCSirona Capital
Malin Corporation
Acorn Bioventures
BVF Partners
Foresite Capital
Janus Henderson Investors
TCGX
Avidity Partners
Source: Dealroom Talent Intelligence.
Global footprint
across markets
Patents
2 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about CG Oncology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CG Oncology on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.